68Ga-DOTA-WL12与FDG PET/CT预测头颈鳞癌免疫化疗反应比较
本前瞻性研究纳入34例组织学确诊的头颈鳞癌患者,比较68Ga-DOTA-WL12与18F-FDG PET/CT在评估PD-L1表达及预测化学免疫治疗反应中的价值。结果显示68Ga-DOTA-WL12 SUVmax在PD-L1阳性病灶和应答者中显著更高,且为治疗反应的独立预测因子,表现优于18F-FDG。
要点
- 68Ga-DOTA-WL12 SUVmax在PD-L1阳性病灶显著高于阴性病灶,可用于非侵入性评估PD-L1表达
- 治疗前68Ga-DOTA-WL12 SUVmax是化学免疫治疗反应的独立预测因子,可辅助筛选获益患者
- 18F-FDG SUVmax在PD-L1阳性和阴性病灶之间及应答者和非应答者之间均无显著差异
核心结论
- 68Ga-DOTA-WL12 PET/CT在评估PD-L1表达和预测化学免疫治疗反应方面优于18F-FDG PET/CT
- 68Ga-DOTA-WL12 SUVmax是预测头颈鳞癌患者化学免疫治疗反应的有前景的影像生物标志物
研究设计与样本
- 前瞻性研究,纳入34例组织学确诊的头颈鳞癌患者,中位年龄59岁(范围32-82岁),男性26例
- 所有患者均行68Ga-DOTA-WL12与18F-FDG PET/CT检查,病灶分析纳入34例患者的37个病灶
- PD-L1表达通过免疫组化评估,17例接受化学免疫治疗且有完整随访的患者纳入治疗反应分析
- 统计分析采用非参数检验、DeLong检验和多变量logistic回归
关键影像表现/征象
- 病灶水平分析中,68Ga-DOTA-WL12 SUVmax在PD-L1阳性病灶显著高于阴性病灶(2.7 vs 1.7,p<0.001)
- 18F-FDG SUVmax在PD-L1阳性与阴性病灶之间无显著差异
- 17例接受化学免疫治疗患者中,68Ga-DOTA-WL12 SUVmax在应答者显著高于非应答者(2.7 vs 1.3,p=0.002)
- 18F-FDG摄取指标在应答者和非应答者之间无鉴别意义
诊断标准与关键数值
- 识别PD-L1阳性病灶时,68Ga-DOTA-WL12 SUVmax的AUC为0.92,显著高于18F-FDG的AUC 0.69(p=0.003)
- 68Ga-DOTA-WL12 SUVmax是治疗反应的唯一独立预测因子(比值比12.42,95%CI:2.08-74.15,p=0.006)
临床应用与阅片要点
- 治疗前68Ga-DOTA-WL12 PET/CT可帮助识别PD-L1阳性病灶,为头颈鳞癌患者免疫治疗决策提供无创影像依据
- 68Ga-DOTA-WL12 SUVmax可用于预测化学免疫治疗反应,协助筛选最可能获益的患者
- 18F-FDG PET/CT在预测PD-L1表达及治疗反应方面价值有限,不应单独作为该适应证的评价手段
局限性
- 治疗反应分析仅纳入17例接受化学免疫治疗且有完整随访的患者,样本量较少
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the value of 68Ga-DOTA-WL12 PET/CT in predicting programmed death-ligand 1 (PD-L1) expression and chemo-immunotherapy response in patients with head and neck squamous cell carcinoma (HNSCC).
MATERIALS AND METHODS: This prospective study enrolled participants with histologically confirmed HNSCC who underwent both 68Ga-DOTA-WL12 and 18F-FDG PET/CT. PD-L1 expression was evaluated by immunohistochemistry; lesion-based analysis compared maximum standard uptake value (SUVmax) of both tracers between PD-L1-positive and -negative lesions. Patients receiving chemo-immunotherapy with available follow-up were included in the patient-based analysis for treatment response. Nonparametric tests, DeLong test, and multivariable logistic regression were employed.
RESULTS: Thirty-four participants(median age, 59 years [range, 32-82 years]; 26 men) were enrolled. In the lesion-based analysis (37 lesions from 34 patients), 68Ga-DOTA-WL12 SUVmax was significantly higher in PD-L1-positive than -negative lesions (2.7 vs 1.7, p < 0.001), whereas 18F-FDG uptake did not differ. For identifying PD-L1 positivity, the AUC for SUVmax of 68Ga-DOTA-WL12 was significantly higher than that of 18F-FDG (0.92 vs 0.69, p = 0.003). Of these participants, 17 received chemo-immunotherapy with complete follow-up and were included in the treatment response analysis. 68Ga-DOTA-WL12 SUVmax was significantly higher in responders than non-responders (2.7 vs 1.3, p = 0.002), while 18F-FDG metrics were not discriminatory. 68Ga-DOTA-WL12 SUVmax was the only independent predictor of treatment response (Odds ratios, 12.42; 95% CI: 2.08, 74.15; p = 0.006).
CONCLUSION: 68Ga-DOTA-WL12 PET/CT outperforms 18F-FDG PET/CT in assessing PD-L1 expression and predicting chemo-immunotherapy response in HNSCC. 68Ga-DOTA-WL12 SUVmax is a promising imaging biomarker for selecting patients likely to benefit from chemo-immunotherapy.
KEY POINTS: Question Whether 68Ga-DOTA-WL12 PET/CT can non-invasively predict PD-L1 expression and chemo-immunotherapy response in patients with HNSCC remains unclear. Findings 68Ga-DOTA-WL12 PET/CT was superior to 18F-FDG PET/CT in identifying PD-L1-positive lesions and independently predicting response to chemo-immunotherapy in HNSCC. Clinical relevance Pre-treatment 68Ga-DOTA-WL12 PET/CT helps identify PD-L1-positive lesions and predict chemo-immunotherapy response, providing an imaging biomarker and supporting stratification for patients with HNSCC.
引用
- Yao, Zhang, Luo, et al. Comparison of pre-treatment 68Ga-DOTA-WL12 and 18F-FDG uptake in predicting response to chemo-immunotherapy in head and neck squamous cell carcinoma. Eur Radiol. 2026. PMID: 42732027. doi:10.1007/s00330-026-12865-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。